IL24 and non-small cell lung carcinoma: This observation was further extended by Gupta et al. who demonstrated that combination treatment of either GST-MDA-7 or GST-M4 (a truncated version of MDA-7/IL-24) and Tarceva (erlotinib) at sub-optimal doses synergistically inhibited non-small cell lung carcinoma (NSCLC) cell growth and enhanced apoptosis as compared to either agent alone [148].